Eiger BioPharmaceuticals, Inc. Class Action Lawsuit - EIGR

(i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the EIGR class action lawsuit, you must have incurred a loss on shares of Eiger purchased during the class period listed above.

If you suffered a loss in Eiger during the relevant time frame or pursuant to the relevant offering(s), you have until January 9, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.